Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC after interval CRS in ovarian cancer
NCT03540017Phase 1Unknown
- Sponsor
- Northwell Health
- Start
- Mar 2019
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cisplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC), sponsored by Northwell Health. Primary endpoints: Morbidity assessed by adverse events and serious adverse events at 30 days, Safety data obtained from scheduled exams at 1 year and 1 more. Status: unknown.
02
Drugs
cisplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT03540017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03540017.